These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 15584983)

  • 41. Variant Creutzfeldt-Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty.
    Farrugia A; Ironside JW; Giangrande P
    Vox Sang; 2005 Nov; 89(4):186-92. PubMed ID: 16262750
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effects of leukodepletion on the generation and removal of microvesicles and prion protein in blood components.
    Krailadsiri P; Seghatchian J; Macgregor I; Drummond O; Perrin R; Spring F; Prescott R; Williamson L; Prowse C; Anstee D; Turner M
    Transfusion; 2006 Mar; 46(3):407-17. PubMed ID: 16533284
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safe method for isolation of prion protein and diagnosis of Creutzfeldt-Jakob disease.
    Bastian FO; McDermott ME; Perry AS; Carver LA; Dash S; Garry RF
    J Virol Methods; 2005 Dec; 130(1-2):133-9. PubMed ID: 16102852
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products.
    Ludlam CA; Turner ML
    Br J Haematol; 2006 Jan; 132(1):13-24. PubMed ID: 16371015
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Creutzfeldt-Jakob disease: reflections on the risk from blood product therapy.
    Brown P
    Haemophilia; 2007 Dec; 13 Suppl 5():33-40. PubMed ID: 18078395
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lack of evidence of transfusion transmission of Creutzfeldt-Jakob disease in a US surveillance study.
    Dorsey K; Zou S; Schonberger LB; Sullivan M; Kessler D; Notari E; Fang CT; Dodd RY
    Transfusion; 2009 May; 49(5):977-84. PubMed ID: 19170987
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emerging pharmacotherapies for Creutzfeldt-Jakob disease.
    Korth C; Peters PJ
    Arch Neurol; 2006 Apr; 63(4):497-501. PubMed ID: 16606761
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cerebrospinal fluid biomarkers in Creutzfeldt-Jakob disease.
    Van Everbroeck B; Boons J; Cras P
    Clin Neurol Neurosurg; 2005 Aug; 107(5):355-60. PubMed ID: 16023527
    [TBL] [Abstract][Full Text] [Related]  

  • 49. KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity.
    Vetrugno V; Cardinale A; Filesi I; Mattei S; Sy MS; Pocchiari M; Biocca S
    Biochem Biophys Res Commun; 2005 Dec; 338(4):1791-7. PubMed ID: 16288721
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Blood infectivity, processing and screening tests in transmissible spongiform encephalopathy.
    Brown P
    Vox Sang; 2005 Aug; 89(2):63-70. PubMed ID: 16101685
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins.
    Thyer J; Unal A; Thomas P; Eaton B; Bhashyam R; Ortenburg J; Uren E; Middleton D; Selleck P; Maher D
    Vox Sang; 2006 Nov; 91(4):292-300. PubMed ID: 17105604
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficient propagation of variant Creutzfeldt-Jakob disease prion protein using the cell-protein misfolding cyclic amplification technique with samples containing plasma and heparin.
    Oshita M; Yokoyama T; Takei Y; Takeuchi A; Ironside JW; Kitamoto T; Morita M
    Transfusion; 2016 Jan; 56(1):223-30. PubMed ID: 26347231
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Creutzfeldt-Jakob disease: Carnoy's fixative improves the immunohistochemistry of the proteinase K-resistant prion protein.
    Giaccone G; Canciani B; Puoti G; Rossi G; Goffredo D; Iussich S; Fociani P; Tagliavini F; Bugiani O
    Brain Pathol; 2000 Jan; 10(1):31-7. PubMed ID: 10668893
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Blood infectivity and the prospects for a diagnostic screening test in Creutzfeldt-Jakob disease.
    Brown P; Cervenáková L; Diringer H
    J Lab Clin Med; 2001 Jan; 137(1):5-13. PubMed ID: 11150018
    [No Abstract]   [Full Text] [Related]  

  • 55. Blood supplies hit by vCJD fear.
    Strachan-Bennett S
    Nurs Times; 2004 Jan 6-12; 100(1):6. PubMed ID: 14735624
    [No Abstract]   [Full Text] [Related]  

  • 56. Innocent white blood cells in sporadic Creutzfeldt-Jakob disease?
    Lee ST; Roh JK
    Lab Invest; 2009 Jun; 89(6):612-3. PubMed ID: 19474820
    [No Abstract]   [Full Text] [Related]  

  • 57. Size of native and denatured DNA of Ehrlich ascites tumour cells isolated in the presence of different protease concentrations.
    Schroeter D; Werner D; Meinzer P
    Eur J Cell Biol; 1981 Apr; 24(1):131-8. PubMed ID: 7016543
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Scientists race to develop a blood test for vCJD.
    Nat Med; 2001 Mar; 7(3):261. PubMed ID: 11231599
    [No Abstract]   [Full Text] [Related]  

  • 59. Virus-like interference in the latency and prevention of Creutzfeldt-Jakob disease.
    Manuelidis L; Lu ZY
    Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5360-5. PubMed ID: 12692308
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Distribution of cell-associated prion protein in normal adult blood determined by flow cytometry.
    Barclay GR; Hope J; Birkett CR; Turner ML
    Br J Haematol; 1999 Dec; 107(4):804-14. PubMed ID: 10606888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.